Labour Would Review UK PPRS, MCA, ABPI Told

29 January 1996

Although an incoming Labour government would want to maintain the UK pharmaceutical industry's prominent position, it would also want to review the drug approval process, notably the Medicines Control Agency, and look at the Pharmaceutical Price Regulation Scheme, shadow health minister Kevin Barron told an Association of the British Pharmaceutical Industry public relations conference this month.

Labour, he said, wants to support, encourage and build on the industry's achievements, and hopes to work together with it to maintain and improve the infrastructure and relationships that have been the cornerstone of the industry's success since the National Health Service began.

Balance Of PPRS Questioned However, among the platitudes and praise in his speech to the meeting, Mr Barron had a few barbs. For example, in considering the PPRS, he noted that he was not sure that the balance of support for advertising and promotion of drug products is right, and he would want to look at how the PPRS encourages research and controls promotional activities.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight